Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-018-4201-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Low-Dose [18F]FDG-PET/CT Scans: Ensuring Quality Amid Radiotracer Availability Challenges - Insights from a Peripheral Tertiary Care Center.
Indian J Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital & Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.
Background: The introduction of positron emission tomography/computed tomography (PET/CT) has significantly advanced medical imaging. In oncology, F-fluorodeoxyglucose (F-FDG) PET/CT is particularly crucial for staging, evaluating treatment response, monitoring follow-up, and planning radiotherapy. However, in resource limiting hospitals, the availability of fluorine-labeled F-FDG limits optimal scan acquisition.
View Article and Find Full Text PDFNeuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation.
J Cent Nerv Syst Dis
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background: Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Università degli studi di Genova, Genova, Liguria, Italy.
Background: Alzheimer's disease (AD) is the most common form of dementia, predominantly manifesting as amnestic impairment. However, atypical presentations such as logopenic variant of primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), corticobasal syndrome (CBS) and frontal AD pose diagnostic challenges. This study presents preliminary data from a retrospective analysis investigating brain functional differences between typical and atypical AD forms.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.
Background: Biomarkers promise to significantly improve the differential diagnosis of Alzheimer's disease (AD). Plasma biomarkers, such as phosphorylated tau (p-tau), have shown potential in diagnosing AD with high accuracy. Unlike the widely-used [18 F]FDG-PET diagnostic biomarker in clinical practice, plasma p-tau is specific to AD and can provide an affordable and scalable diagnostic tool.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Astrocytes play a main role in brain energy metabolism, primarily through the metabolic cooperation with neurons. The use of [F]fluorodeoxyglucose(FDG)-PET has become a valuable indicator of neurodegeneration in Alzheimer's disease (AD), revealing a brain hypometabolic signature, but it is sensitive to changes in astrocyte metabolism. It is postulated that the activation of the excitatory amino acid transporter 2 (EAAT2) is the main trigger of FDG-PET uptake in astrocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!